Navigation Links
Echo Therapeutics Announces Third Quarter 2011 Financial Results
Date:11/8/2011

PHILADELPHIA, Nov. 8, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, announced results for the third quarter and nine months ended September 30, 2011.  Echo's Quarterly Report on Form 10-Q is available through Echo's website at www.echotx.com.

Recent Corporate Highlights:

  • Echo added key executives to its management team as part of the company's plan to accelerate development of the Symphony tCGM System and other new products.  In August 2011, Marshall ("Mac") Deweese joined Echo as Senior Vice President of Operations and in October 2011, Samir Farah joined the company as Vice President of Product Development.  
  • Echo received registered trademarks for SYMPHONY and PRELUDE, as used with Echo's tCGM system and mechanical skin ablator, respectively.  Echo also received two issued patents covering its Symphony tCGM System. These new patents join eleven U.S. patents and twenty-eight foreign patents already held by Echo.
  • Echo initiated a clinical trial of the Symphony tCGM System in September 2011.  The Company announced positive data from this trial indicating that Symphony successfully monitors patient glucose levels and continues to demonstrate improvements in clinical performance.

  • "As anticipated, much of the third quarter has been focused on the aggressive product development and testing of the Symphony system as exemplified by the favorable clinical trial results and the addition of experienced senior management in operations and product development.  Additionally, the receipt of new patents and registered trademarks for Symphony and Prelude are key components of our intellectual property portfolio," commented Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics. "We continue to remain focused on bringing the Symphony System closer to commercialization as we head toward major catalysts this quarter and early next year."

    Financial Results for the Nine Months Ended September 30, 2011For the nine months ended September 30, 2011, Echo reported approximately $344,000 in total revenues compared to $325,000 in total revenues in the first nine months of 2010. Operating expenses increased by 32% to $6.0 million, compared to $4.5 million during the first nine months of 2010. This increase included a 22% increase in research and development expense and a 41% increase in selling, general and administrative expense. The net loss for the first nine months of 2011 was approximately $7.9 million, or ($0.30) per common share, compared to a net loss of $3.0 million, or ($0.11) per common share, for the same period in the prior year.  The Company completed the quarter with cash of approximately $2.3 million.

    About Echo TherapeuticsEcho Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.  Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

    Cautionary Statement Regarding Forward Looking StatementsThe statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including the safety and efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2010, its Quarterly Reports on Form 10-Q and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

    For More Information:
    Christine H. Olimpio
    Director, Investor Relations and Corporate Communications
    (215) 717-4104

    Connect With Us:- Visit our website at www.echotx.com

    - Follow us on Twitter at www.twitter.com/echotx

    - Join us on Facebook at www.facebook.com/echotxEcho Therapeutics, Inc.Condensed Consolidated Balance SheetsSeptember 30,2011December 31,2010ASSETS(Unaudited)Current Assets:Cash and cash equivalents

    $  2,258,019$  1,342,044Other current assets

    486,800621,693Total current assets

    2,744,8191,963,737Net property and equipment (including assets under capitalized leases)

    306,15948,034Other Assets:Intangible assets, net of accumulated amortization

    9,625,0009,625,000Restricted cash, deposits and other assets

    20,565275,499Total other assets

    9,645,5659,900,499Total assets

    $  12,696,543$  11,912,270LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities:Accounts payable

    $  362,513$  605,634Deferred revenue

    196,290405,454Derivative warrant liability

    1,561,2441,544,996Accrued expenses and other liabilities

    819,870565,546Total current liabilities

    2,939,9173,121,630Deferred revenue, notes payable and capital lease obligation, net of current portion

    97,27688,356Total liabilities

    3,037,1933,209,986CommitmentsStockholders' Equity:Perpetual redeemable preferred stock, Series B

    22Convertible preferred stock, Series C & D

    35,10949Common stock

    344,557311,264Additional paid-in capital

    88,730,32479,646,385Common stock subscribed for but not paid for or issued

    -285,000Accumulated deficit

    (79,450,642)(71,540,416)Total stockholders' equity

    9,659,3508,702,284Total liabilities and stockholders' equity

    $  12,696,543$  11,912,270Condensed Consolidated Statements of Operations (unaudited)Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2011201020112010Licensing revenue

    $  (44,360)$  16,023$  198,550$  197,594Other revenue

    -30,575145,152127,095Total revenues

    (44,360)46,598343,702324,689Operating Expenses:Research and development

    695,019409,3832,557,1182,087,484Selling, general and administrative

    1,527,317546,4463,427,5822,434,944Total operating expenses

    2,222,336955,8295,984,7004,522,428Loss from operations

    (2,266,696)(909,231)(5,640,998)(4,197,739)Other Income (Expense):Interest income (expense), net

    196(2,660)(9,869)(3,195)Gain (loss) on extinguishment of debt/payables

    --(1,514)200,000Gain on disposals of assets

    --834-Derivative warrant liability gain (loss)

    893,229329,051(2,258,679)1,000,987Other income (expense), net

    893,425326,391(2,269,228)1,197,792Net loss

    (1,373,271)(582,840)(7,910,226)(2,999,947)Deemed dividend on repricing warrants

    (87,500)-(87,500)-Accretion of dividends on Convertible Perpetual
    Redeemable Preferred Stock

    (49,519)(37,026)(142,761)(93,700)Deemed dividend on beneficial conversion feature of
    Series D Convertible Preferred Stock

    --(1,975,211)-Net loss applicable to common shareholders

    $  (1,510,290)$  (619,866)$  (10,115,698)$  (3,093,647)Net loss per common share, basic and diluted

    $  (0.04)$  (0.02)$  (0.30)$  (0.11)Basic and diluted weighted average common shares outstanding

    34,295,42529,105,51733,620,75128,809,682
    '/>"/>

    SOURCE Echo Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. PTC Therapeutics Receives Grand Challenges Explorations Funding
    2. Nektar Therapeutics Reports Third Quarter 2011 Financial Results
    3. Pharmacodynamic Data from Syndax Pharmaceuticals ENCORE 301 Study in Advanced Breast Cancer to be Highlighted at the AACR Molecular Targets and Cancer Therapeutics Conference 2011
    4. Regulus Therapeutics Expands Worldwide Patent Coverage on microRNA-122 to Treat Hepatitis C Virus (HCV) Infection
    5. Echo Therapeutics Announces Warrant Exercise by Its Largest Shareholder
    6. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    7. Pearl Therapeutics Presents New Scientific Evidence Supporting Versatility of Its Novel Cosuspension MDI Platform
    8. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
    9. Pneumonia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
    10. Epilepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2018
    11. Osteoarthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/12/2016)... --> ... Global Clinical Trials Review, H2, 2015 provides an ... trials landscape along with top level data related ... & E7), Trial Status, Trial Phase, Sponsor Type ... involved and enlists all trials (Trial title, Phase, ...
    (Date:2/11/2016)... , Feb. 11, 2016 The primary ... and future adoption patterns on the usage of liquid ... the following: - Timeframe of liquid biopsy ... ctDNA, cfDNA and Evs—by organization type - Sample inflow ... types: blood, saliva, stool, serum, and so on. - ...
    (Date:2/11/2016)... 2016 PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial ... 2015. The Company also filed its Quarterly Report on Form ... the Securities and Exchange Commission today. --> ... --> --> Net sales for ... or 95%, to $5.4 million from $2.8 million for the ...
    Breaking Medicine Technology:
    (Date:2/13/2016)... ... February 13, 2016 , ... In the early or “honeymoon” stage ... to perfection, go out of their way to be romantic, and may exaggerate a ... look at any online dating profile. , A recent study from Queendom.com ...
    (Date:2/12/2016)... ... February 12, 2016 , ... ... Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills needed to introduce and ... U.S. universities who will draw from Siemens’ deep knowledge of product development ...
    (Date:2/12/2016)... ... February 12, 2016 , ... As a former television executive, owner Tal Rabinowitz ... no time to decompress, Rabinowitz found herself drawn to a casual meditation class while ... on her life, implementing a 20-minute-per-day meditation practice with her team. After her tenure ...
    (Date:2/12/2016)... ... February 12, 2016 , ... Every winter, someone is killed, injured ... West Penn Burn Center, part of the Allegheny Health Network, has partnered ... you the “Space Heaters Need Space” campaign. , “Space Heaters Need Space” ...
    (Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Erlanger Agency ... the greater Columbus, OH area. The latest campaign focuses on the fight against breast ... Donations are now being accepted here . , Carmen is a loving single ...
    Breaking Medicine News(10 mins):